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ABSTRACT
Background and the purpose of the study: During the last two decades one of the most important 
problems in drug formulations has been low aqueous solubility of new molecules. However, 
numerous techniques, such as milling, co-solvent solubilization and solid dispersion have been 
used conventionally for aqueous solubility enhancement and the rate of solubility.  Recently, 
nanoparticle  engineering  processes  have  been  developed  and  reported  for  pharmaceutical 
applications to increase the dissolution rate of low-soluble drugs which in turn may leads to 
substantial increases in bioavailability. In this study, a controlled precipitation method was used 
to produce indomethacin nano-solid suspension in a polymeric matrix (as a model), in order to 
increase the solubility and rate of the dissolution of poorly soluble model drug. 
Methods: Nano-solid suspension of indomethacin in polyvinyl pyrrolidine (PVP) was prepared 
by controlled precipitation technique, characterized by differential scanning calorimetry (DSC), 
X-ray diffraction (XRD), Fourier Transform Infrared Spectroscopy (FTIR) and evaluated for in 
vitro solubility and dissolution rate.  
Results and major conclusion: Absence of thermal and diffractional peaks in DSC and XRD 
studies  indicated  that  indomethacin  interacts  with  PVP  in  solid  phase.  The  solubility  of 
indomethacin in nano-solid suspension compared to crystalline form was increased to about 
four-fold.  It was found that particle size distribution depend to the polymer MW and drug: 
polymer ratios.  Spectroscopy methods and Transmission Electron Microscopy (TEM) images 
showed that indomethacin dispersed as amorphous nanosize particles in freeze dried powder.   
Enhanced solubility and dissolution rate of indomethacin compared to physical mixtures and 
crystalline form of indomethacin (polymorph I), demonstrated that it interacts with PVP via 
hydrogen bond and probably forming eutectic mixture.   
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INTRODUCTION
During the last two decades one of the problems 
raised  in  pharmaceutical  technology  has  been 
poor aqueous solubility and/or dissolution rate of 
the  new  molecules  (1).  Pharmaceutical  scientists 
are constantly seeking new approaches in order to 
obtain an adequate oral bioavailability. Recently, the 
formulation of drugs as nanoscale systems (which 
have a size below 1µm) has rapidly evolved as a 
drug delivery strategy (2). The major characteristic 
of these systems is the rapid dissolution rate, which 
enhance bioavailability after oral administration (3).
Current techniques used to obtain drug nanoparticles 
can be divided into two categories: The first comprises 
the bottom-up processes that build up particles from 
dissolved drug molecules (e.g. aerosol flow reactor 
method) (4), microemulsion template methodology 
(5),  supercritical  fluid-based  technologies  (6), 
high  gravity  reactive  precipitation  (7),  controlled 
precipitation (8) and the melt emulsification method 
(9).  The  second  category  consists  of  top-down 
processes that are based on breaking down larger 
particles e.g. media milling (2) and high-pressure 
homogenization  (10).  Typically,  these  production 
processes  are  conducted  in  liquid,  hence  forming 
a nanosuspension. As the total surface area of the 
resulting  nanosuspension  particles  is  typically 
several  orders  of  magnitude  larger  compared  to 
a  coarse  suspension,  large  quantities  of  additives 
may be necessary to ensure adequate stabilization. 
Although,  all  marketed  products,  currently  are 
produced by so-called top-down techniques, in which 
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µm). The particles were formed spontaneously after 
decreasing the pH to 5.5-6 by 1M HCl solution.  The 
nano-solid suspensions prepared, was cooled rapidly 
to -70 °C and stored overnight.  Freeze-drying of the 
samples was performed with a Telstar freeze-dryer 
(Terrassa, Spain) at a shelf temperature of −50 °C 
with a pressure below 1 mbar, then the vials were 
removed after 48 hrs of drying. The samples were 
stored  in  well  closed  glass  container  at  -20  °C  for 
more investigations. Previous studies have shown that 
pure amorphous indomethacin in this temperature is 
physically stable for at least 6 months (16)
Particle size distribution
Particle size distribution after re-dispersion of the 
freeze–dried samples was measured with dynamic 
photon  correlation  spectroscopy  technique  (PCS) 
using  a  Zetasizer  SZ3000  (malvern  instrument, 
worcestershier, UK.). All the presented data are the 
mean value of three independent samples produced 
under identical production conditions. 
The morphology of the nanoparticles was examined 
by  Transmission  Electron-Microscopy  (CM  12 
Philips, Eindhoven, Netherlands).
X-ray powder diffraction
Samples of each indomethacin-PVP co-percipitate 
were  placed  into  tightly  sealed  vials  and  stored 
at -20 °C.  The extent of any physical change or 
crystallization over a 20-days period was determined. 
The  X-ray  data  were  collected  with  a  SEIFERT-
3003 PTS X-ray generator with Cu rotating anode 
(Germany), 40 kW, 30 mA and scanning speed 4°.  
Fourier Transform Infrared Spectroscopy (FT-IR)
The fourier transform infrared spectroscopy (FT-IR) 
spectra  were  obtained  using  FT-IR  Shimadzu 
(FT-IR  prestige  21).  The  samples  (indomethacin, 
PVP, physical mixtures or nano-solid dispersions) 
were grounded and mixed thoroughly with potassium 
bromide, at 1:5 (sample:potassium bromide) weight 
ratio. The potassium bromide discs were prepared 
by compressing the powders at a pressure of 5 tones 
for 5 min in a hydraulic press. Scans were obtained 
at a resolution of 2 cm−1, from 2000 to 500 cm−1. 
Differential Scanning Calorimetry (DSC)
Thermal  characteristics  of  the  pure  materials,  the 
physical mixtures and nano-solid suspensions were 
determined by an automatic thermal analyzer system 
(Shimadzu, DSC– 60).  Accurately weighed samples 
(5–8 mg) were placed in nonhermetically aluminium 
pans and heated against an empty aluminium pan as 
a reference. Heating rate was 5 °C/min and nitrogen 
purge 20 ml/min.
Determination of indomethacin content in lyophilized 
samples
The indomethacin content in samples was analysed 
the nanoparticles are obtained through size reduction 
into  the  submicron-range,  bottom-up  techniques 
and especially controlled precipitation method, are 
methods of interest for nanozation of poorly soluble 
drugs.  In this method without any harsh conditions 
and only with simple equipments one could reduce 
the particle size to few hundred nanometers range. 
Therefore, whatever method which is used for the 
production of nanosuspensions, a careful evaluation 
of  the  type  and  concentration  of  the  stabilizer  is 
a  critical  stage  for  the  successful  production  of 
nanosuspensions.  Both  polymeric  and  surfactant 
stabilizers can be used for this purpose (11). 
Indomethacin is a non-steroidal, anti-inflammatory 
drug  (NSAID)  with  anti-pyretic  and  analgesic 
properties.  It is categorized as Class II drug that has 
poor solubility and high permeability.  Some studies 
have shown that the solubility and dissolution rate 
of  poorly  soluble  drugs,  such  as  indomethacin  is 
enhanced, in combination with high soluble excipeints 
as solid dispersion (12, 13).  In the previous study it 
was shown that the dispersion of indomethacin co-
percipitate with Polyvinyl Pyrrolidone (PVP) is in 
the colloidal form and the samples were stable for a 
long lasting time (14) .
The  aim  of  this  study  was,  firstly  to  investigate 
the  feasibility  of  preparation  of  indomethacin 
copercipitation,  as  vehicle  for  enhancement  of 
wettability and decreasing agglomerative properties of 
indomethacin nanoparticle, and finally to investigate 
the solubility and  dissolution rate of the model drug.
MATERIAL AND METHOD
Materials
Indomethacin,  [1-(p-chlorobenzoyl)-5-methoxy-
2-methylindole-3-acetic  acid],  as  the  γ  crystal  form 
was kindly gifted by Behdasht Kar Co., (Tehran-Iran).   
The α-polymorph of indomethacin was prepared by 
dissolving the γ crystal form in boiling methanol and 
precipitated with water at room temperature as reported 
by Kaneniwa et al. (15).  Purity of two polymorphs was 
determined  by  wide-angle  X-ray  scattering  pattern.   
Polyvinyl Pyrrolidone (PVP) K-25, K-40 and K-360 
were purchased from Sigma-Aldreich, (USA).  All 
other reagents were analytical grades and purchased 
from Merk Co., (Germany).  Ultrapure water (Millipore, 
Direct QTM, France) was used throughout the study.
Methods
Preparation of IND nanoparticles
Indomethacin nano-solid suspensions were prepared 
by control pH precipitation followed by freeze dried 
technique. Briefly, co-percipitates  of indomethacin-
PVP were prepared over the range of 10- 95% w/w 
PVP  (1:9  to  19:1  polymer-drug  ratio).    Different 
ratios  of  indomethacin  and  PVP  were  dissolved  in 
ultra-pure water by adding 20 µl of 1M NaOH, and 
then the samples passed through membrane filter (0.2 
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by dissolving 10 mg of samples in 10 ml of 0.1 M 
methanolic HCl (USP).  The samples were stirred on 
a magnetic stirrer at 100 rpm at room temperature 
for  one  hour,  filtered  (0.22  µm,  millipore®)  and 
diluted with above medium.  The amount of drug 
was  determined  spectrophotometrically  (Jenway 
6505, Dae II Science Co., South Korea) at 259 nm 
against 0.1 M methanolic HCl as blank.
 
Determination of indomethacin solubility 
All the solubility experiments were carried out using 
the analytical isothermal shake-flask method. The 
aqueous solubility of indomethacin was measured at 
25 °C.  Saturated solutions were prepared by mixing 
an excess of solid solute and 20 ml of water into a 
constant-temperature jacketed glass cells and stirring 
for 2 days, filtered (cut off, 0.22 µm, millipore®) and 
the content of dissolved indomethacin was analysed 
spectrophotometrically at 259 nm.  
In-vitro release study
Ten milligrams of lyophilized samples containing 
indomethacin and PVP were suspended in 300 ml 
of 0.1 M HCl to maintain sink conditions and stirred 
on a magnetic stirrer at 50 rpm (Kavosh Dissolution 
Tester, Tehran, Iran) at room temperature. At pre-
determined  time  intervals,  5  ml  aliquots  were 
withdrawn,  filtered  (cut  off  0.22  µm)  and  the 
amount of dissolved indomethacin was determined 
spectrophotometrically. A physical mixture containing 
10 mg of micronized indomethacin and PVP in 300 
ml of 0.1 M HCl was used as reference dispersion 
for the dissolution test. Each dissolution experiment 
was performed in triplicates and the average values 
and standard deviations were calculated.
Statistical analyses 
Effect  of  MW  and  drug  ratio  on  particle  size 
distribution and dissolution rate was determined using 
unpaired student’s t-test. Significance was tested at 
the 0.05 level of probability. Statistical analysis was 
performed with the software package SPSS® 11.
RESULTS AND DISCUSSION
Some  researchers  have  previously  shown  that 
numerous polymers such as PVP can improve the 
solubility and dissolution rate of low soluble drugs 
(13).  Moreover, it has been reported that PVP has 
an  inhibitory  effect  on  re-crystallization  rate  of 
indomethacin in amorphous solid dispersions (17).   
In addition, it has been shown that the crystallization 
rate of indomethacin is dependent on its molecular 
mobility in solid dispersion phase (18). Therefore, 
it  has  been  suggested  that  PVP  can  interact  with 
indomethacin via hydrogen bond and consequently 
prevent  re-arrangement  of  drug  molecules  to 
crystalline  form.  In  the  previous  report  it  has 
been  shown  that  indomethacin  dispersion  within 
polymeric matrix in solid phase was colloidal form 
(14).  So, it is logical to accept that this polymer can 
entrap particulated indomethacin at nano-range and 
in amorphous state for a long lasting time. 
Based  on  the  above  comments,  it  was  found 
important to investigate whether polymer molecular 
weight and drug ratio have any effect on particle size 
distribution and stability of indomethacin nano-solid 
suspensions.
Preparation of polymorph II of indomethacin  
Indomethacin is known to exist in more than one 
non-solvated crystalline form. Most investigations 
refer to these polymorphs as forms I and II. Form I is 
the highest melting and lowest solubility polymorph 
and  therefore,  it  is  the  thermodynamically  stable 
crystalline  form  of  indomethacin.  During  the 
preparation of indomethacin nano-solid suspension, 
formation  of  metastable  form  of  crystalline 
indomethacin  (form  II)  is  probable.    In  order  to 
investigate the physical properties of this polymorph, 
it  was  prepared  according  to  Kaneniwa  method 
(15).  FT-IR and X-ray diffraction pattern of these 
polymorphs are shown in figures 1 and 2.
Effect of polymer MW and drug ratio on particle 
size
In  order  to  assess  the  effect  of  polymer  type  on 
particle size and stability of indomethacin nano-solid 
suspension,  three  types  of  PVP  were  employed.   
The particle size range of dispersed indomethacin 
within polymeric matrix is shown in table 1.  These 
data which are in agreement with previous report 
(19) show that the nature of the polymers used in 
solid dispersions has a minor effect on the stability 
behavior of nano-solid dispersion systems.  In other 
word,  the  ratios  of  drug:  polymer  and  capability 
of the polymer binding to indomethacin molecules 
are  the  most  important  factors  which  determine 
indomethacin  crystallinity  or  amorphous  states  in 
solid phase (18). This is a logical result, because 
rate of the crystallization of drug from amorphous 
state is known to be related to molecular mobility in 
solid phase (20). Therefore, a high molecular weight 
polymer  with  a  high  glass  transition  temperature 
(Tg)  will  raise  the  viscoelastic  properties  of  the 
mixture and decrease the mobility of dispersed drug 
relative to drug alone and consequently reduce the 
tendency  for  crystallization.  These  results  are  in 
Table 1. Effect of polymer MW and drug ratio on the particle size and 
polydispersity index of selected nano-solid suspension formulation. 
PI= polydispersity index
(n=3)
Type system Intrinsic solubility* Relative solubility**
Nano-solid suspension 5.86±1.2 6.45
Physical mixture 2.30±0.51 2.53
Polymorph I 0.91±0.26 1.00
Polymorph II 1.44±0.34 1.59
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agreement with pervious finding (21, 22), in which 
it has been reported that PVP has an inhibitory effect 
on amorphous nanoparticle re-crystallization during 
freeze–drying cycles. 
Particle size and TEM micrograph of indomethacin 
nanoparticles, after re-dispersion of the freeze–dried 
samples, was measured by DLS technique (Table 1) and 
TEM (Figure 3) respectively.  Base on the results, it 
seems that mean of the particle size of indomethacin 
nano-solid suspension increase as polymer MW and 
drug ratio increased. Furthermore, the polydispersity 
index  (PI)  values,  which  define  the  particle  size 
distribution,  indicated  that  the  samples  prepared 
with high MW polymer (PVP-360) and have low 
drug  contents  are  more  homogenous  than  those 
prepared  with  low  MW  polymer  (PVP-10) 
and  high  drug  ratio.  This  result  indicates  that 
indomethacin interactions with PVP-10 are higher 
than  with  PVP-360,  but  lower  viscoelasticity 
property  of  PVP-10  than  PVP-40  and  PVP-360 
can  not  prevent  aggregation  of  re-dispersed 
nanoparticles  with  each  other  effectively.  The 
results confirm that the protective effect of PVP on 
nanoparticle agglomeration is affected by the drug 
ratio and polymer MW. Previous study has shown 
that the amount of interactions of indomethacin-PVP 
increased by decrease of PVP molecular weight. The 
greatest extent of interactions was found in the solid 
dispersion prepared with PVP K10 (17). 
FT-IR analysis
Figure. 2 shows the FT-IR spectra of indomethacin 
(polymorph I & II), PVP, physical mixture and nano-
solid suspension system (1:2). The pattern of C=O 
stretch vibrations is typically observed in the range 
of  1600-1750  cm-1.    The  indomethacin  molecule 
contains two carbonyl groups of the benzoyl and 
carboxyl moieties. It was suggested that the peaks 
present  in  this  range  must  be  attributed  to  the 
asymmetric  benzoyl  stretching,  while  the  peak  at 
1692 cm-1 is assigned to benzoyl vibration (20). In the 
form II and amorphous indomethacin, the benzoyl 
vibration occurs at a lower wave number (1688 and 
1684 cm-1 respectively).  Three other peaks of lower 
intensity are observed at lower frequencies: 1580, 
1590 and 1621 cm-1. PVP shows only a broad and 
rounded peak (centered at 1666 cm-1) in this range, 
which it is attributed to the amide carbonyl of the 
PVP  units.  The  three  types  of  PVP,  which  were 
employed to prepare solid dispersions, K10, K40 and 
PVP K360, differing in MW, cannot be distinguished 
by IR spectra, because the monomers have identical 
backbone, differing only in chain length. 
All indomethacin peaks in the nano-solid dispersion 
system are shifted (1679, 1614, 1590 and 1577 cm-1, 
A
A
B
C
D
E
B
C
D
E
Figure  1.  FT-IR  pattern  of A)  IND  (polymorph  I),  B)  IND 
(polymorph  II),  C)  IND:PVP  (1:2)  physical  mixture,  D) 
IND:PVP (1:2) nano-solid suspension and E) pure PVP.
Figure 2. Powder X-ray diffraction pattern of IND:PVP nanosuspensions 
samples: A) IND (polymorph I), B) IND (polymorph II), C) IND:PVP 
(2:1) physical mixture, D) IND:PVP (2:1) nanosuspension and E) PVP 
cm-1
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respectively)  and  the  spectrum  appears  simple. 
These results indicate that the crystalline structure of 
indomethacin in solid dispersions with PVP change 
to amorphous state and/or indomethacin molecules 
interact with carbonyl moiety of  pyrrolidone ring 
of PVP by hydrogen bonds and make an eutectic 
mixture (21).  These results are in agreement with 
earlier reports (9, 23).
Differential scanning calorimetry studies
Indomethacin interactions in nano-solid suspensions 
and  physical  mixture  were  investigated  using 
DSC studies.  The DSC curve of 1:1 ratio of pure 
indomethacin polymorphs exhibits two endothermic 
peaks with onset temperature of 148.15 °C and 158.83 °C 
respectively (Figure 4).  It should be remembered 
that form II of indomethacin is a metastable form 
and re-crystallized to form I after melting at 148.15 °C.   
So, the endothermic picks are not equal.  There are 
two  negligible  endothermic  changes  in  the  DSC 
curve  of  nano-solid  suspension  of  indomethacin-
PVP in the ratio of 1:2. Considering XRD pattern 
and FT-IR spectrum of nano-solid suspension one 
could  presume  that  the  indomethacin  and  PVP 
interact  via  hydrogen  bond  and  forms  a  eutectic 
mixture. The first endothermic change appears as a 
board fluctuation in baseline with onset temperature 
at about 25 °C and the second as low broad peak 
with onset temperature at about 90 °C. These results 
suggest the formation of a eutectic system between 
the drug and polymer. In this case, the peak at the 
lower  temperature  belong  to  the  melting  of  the 
eutectic mixture, and the second, peak which change 
at the higher temperature, indicate the melting of the 
surplus component. From the position of the second 
peak one could assume, that indomethacin is left 
over component after formation of eutectic mixture. 
To  confirm  this  assumption  a  physical  mixture 
composed of indomethacin and PVP in 2:3 ratio was 
scanned (data not shown). The peak of the eutectic 
appeared larger and the second peak was smaller than 
the DSC curve of lyophilized nanosuspensions with 
2:1 ratio of components. These results demonstrate 
that the composition of the lyophilized sample is not 
in a eutectic ratio, but contains some excess of drug. 
(24). Therefore, the increase in the rate of dissolution 
of the drug can be explained by formation of the 
eutectic system and sub-micron sized drug particles 
during the production of nanosuspensions. 
These data were supported with XRD studies.  XRD 
patterns  curves  of  PVP,  indomethacin,  physical 
mixture,  and  nano-solid  suspension  are  shown 
in  figure  2.  Narrow  and  symmetrical  peaks  in 
indomethacin  diffractogram  (2θ=10-60°)  indicate 
crystalline structural of this material.  PVP on the 
contrary is dominantly amorphous in nature as indicated 
in its diffractogram.  Evaluation of pure indomethacin, 
physical  mixture  and  nano-solid  suspension  XRD 
diffractograms  show  that  crystalline  indomethacin 
(form I&II) undergo to amorphous state after dispread 
in solid state as freeze dried nanosuspensions.  
Solubility  and  dissolution  studies  of  lyophilized 
nano-solid suspensions
Indomethacin is a weak organic acid, with pKa of 4.5 
(25) and its solubility increases with pH.  In order 
to simulate gastric condition for dissolution studies, 
a HCl (0.1 M) medium was selected to slow the 
dissolution rate of the drug, and as a result to allow 
greater discrimination of processing effects. 
The dissolution profiles of lyophilized indomethacin 
nano-solid  suspensions,  in  comparison  with 
a  reference  physical  mixture  of  micronized 
indomethacin (Polymorph I & II) are shown in figure 5.   
The dissolution rate was markedly enhanced in the 
nanomatere-sized system, as more than 45 percent 
of drug dissolved in 30 min, as opposed to less than 
10% of micronized drug in physical mixtures. This 
could be due to the increase in the surface area of the 
drug and possibly better wettability and dispersion 
of  nano-solid  suspensions  in  dissolution  medium. 
In previous study, it was shown that the dissolution 
rate  of  nano-solid  suspensions  is  dependent  to 
polymer  MW  (14)  and  increased  by  decrease 
the  polymer  MW.  In  order  to  study  the  effect  of 
PVP  on  solubility  of  indomethacin,  intrinsic  and 
relative  solubility  of  indomethacin  in  nano-solid 
Type system Intrinsic solubility* Relative solubility**
Nano-solid suspension 5.86±1.2 6.45
Physical mixture 2.30±0.51 2.53
Polymorph I 0.91±0.26 1 .00
Polymorph II 1.44±0.34 1.59
Table  2.  Comparison  of  intrinsic  and  relative  solubility  of 
indomethacin in different state. 
*   mg/100 ml of medium (n=3)
** relative to polymorph I
Figure 3. TEM micrograph of indomethacin nanoparticles released 
from  freeze-dried  nano-solid  suspension  (9:1)  drug:polymer 
ratio. Ten µl of medium was taken immediately after dissolving 
the freeze-dried sample in ultrapure water.  
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suspension  and  physical  mixture  of  micronized 
indomethacin  in  comparison  with  forms  I&II  of 
indomethacin  as  a  reference  were  investigated 
(Table  2).  Intrinsic  solubility  of  indomethacin  in 
both physical mixture and solid dispersion in the 
presence of PVP significantly increased (p <0.05).   
This phenomenon can be explained by solubilization 
effects  of  PVP.  Solubilization  is  likely  to  occur 
through the following mechanisms. In the dry state, 
drug particles were in close contact or adhered to 
the polymer particles as a result of mixing. When 
the mixture came in contact with water, the polymer 
particles might have hydrated rapidly into polymer 
solution, solubilizing the adjacent drug particles and 
subsequently  releasing  the  drug  into  the  medium 
(26). This  could  also  possibly  explain  the  higher 
solubility of drug in phase solubility study where 
the indomethacin particles were already dispersed 
in aqueous polymer solutions. Enhanced solubility 
and dissolution rate of indomethacin from physical 
mixtures could be possibly because of the combined 
action  of  the  surface  activity,  solubilization  and 
wetting effect of PVP (27- 29).   
It could be possible that high MW polymers (such as 
PVP K 360) in dissolution medium produce a viscose 
layer  around  nanoparticles  released  from  freeze-
dried nano-suspension and obstacle the molecular 
diffusion to dissolution medium.  Therefore, a lag 
time in dissolution rate of indomethacin could be 
logical (13).  
It  has  been  reported  that  a  progressive  reduction 
in  particle  size  corresponds  to  increases  in  the 
surface/volume  ratio  and  the  escaping  tendency 
of  the  molecules  until  the  nature  of  the  surface 
Temp (C)
Figure  4.  Differential  scanning  calorimeter  thermograms  of 
indomethacin (form I& II), PVP and nano-solid suspension (1:2).
Figure 5. Dissolution profile of pure indomethacin (form I&II), 
physical mixtures and nano-solid dispersions, drug:polymer ratio (2:1).
dominates the properties of the material.  According 
to  Thomson-freundlich  equation,  saturation 
solubility  of  low  soluble  drugs  is  increased  by 
decrease in particle size (30).  However, this effect 
is only pronounced for particle below approximately 
2 µm, especially with those of lower than 1 µm (31).   
So, reduction of the particle size of poorly soluble 
drugs such as indomethacin has an influent effect 
on dissolution rate, drug solubility and consequently 
bioavailability.  The bioavailability of indomethacin 
is  dependent  to  dissolution  rate  and  particle  size 
reduction can improve the drug efficacy (32).
CONCLUSION
Nano-solid  suspensions  of  indomethacin  in  PVP 
were prepared using a controlled pH co-precipitation 
method.  Spectroscopic  evidence  clearly  indicates 
that the drug molecules interactions with carbonyl 
groups of the polymer was dependent to polymer 
MW and drug ratios. The kinetics of drug release 
from the nano-solid suspension was superior to that 
of  either  indomethacin  or  the  drug–PVP  physical 
mixture, which was attributed to the simultaneous 
particle size reduction, the loss of crystallinity, and 
increased  wettability  due  to  the  presence  of  the 
hydrophilic polymer.
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